Reaction Details Report a problem with these data
Target
Malignant T-cell-amplified sequence 1
Ligand
BDBM345322
Substrate
n/a
Meas. Tech.
Assay 4: MCT1-Mediated Lactate Transport in BT20 Breast Cancer Cells
IC50
26000±n/a nM
Citation
 Parnell, KM; McCall, J MCT4 inhibitors for treating disease US Patent  US10202350 Publication Date 2/12/2019 
Target
Name:
Malignant T-cell-amplified sequence 1
Synonyms:
MCT-1 | MCT1 | MCTS1 | MCTS1_HUMAN | Multiple copies T-cell malignancies
Type:
Enzyme Catalytic Domain
Mol. Mass.:
20563.62
Organism:
Homo sapiens (human)
Description:
n/a
Residue:
181
Sequence:
MFKKFDEKENVSNCIQLKTSVIKGIKNQLIEQFPGIEPWLNQIMPKKDPVKIVRCHEHIEILTVNGELLFFRQREGPFYPTLRLLHKYPFILPHQQVDKGAIKFVLSGANIMCPGLTSPGAKLYPAAVDTIVAIMAEGKQHALCVGVMKMSAEDIEKVNKGIGIENIHYLNDGLWHMKTYK
  
Inhibitor
Name:
BDBM345322
Synonyms:
2-([1-[(2-Chlorophenyl)methyl]-5-(3-methoxyphenyl)-1H-pyrazol-3-yl]methoxy)-2-methylbutanoic Acid | US10202350, Example 68 | US10214492, Example 68 | US11292767, Example 68 | US11724989, Example 68
Type:
Small organic molecule
Emp. Form.:
C23H25ClN2O4
Mol. Mass.:
428.909
SMILES:
CCC(C)(OCc1cc(-c2cccc(OC)c2)n(Cc2ccccc2Cl)n1)C(O)=O
Structure:
Search PDB for entries with ligand similarity: